Akebia Therapeutics, Inc.

NASDAQ:AKBA

Biotechnology

Healthcare
$0.41 +0.49%

+$0.01 today

Market cap
$113.54M
Beta
0.25
P/E (TTM)
-13.3
EPS (TTM)
-$0.08
52W Low $0.82High $4.08

Volume 7.09M

Average 4.03M

AKBA Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Akebia Therapeutics, Inc.NASDAQ: AKBA

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development grows, but more slowly than its trailing trend

Q1 FY2026 research & development of $14.81M rose 51.8% year over year, behind the +78.1% change in trailing-twelve-month research & development. Sequentially, it fell 44.4% from the prior quarter. Over 3 fiscal years it compounded at -27.8% a year.

Context

  • Research & development amounted to 26.4% of revenue in FY2025, up 2.9 pp from a year earlier.
  • Research & development increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from +51.8% toward the trailing-twelve-month pace of +78.1%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$14.81M-44.4% QoQ
Last fiscal yearDec 2025
$62.36M+65.6% YoY
LTMMar 2026
$67.09M+78.1% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+51.8%——
1 year+65.6%——
3-year CAGR-27.8%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
62.36M USD
Year-over-year change
+65.6%
4-year CAGR
-19.4%

Research & Development vs competitors

How AKBA compares with its peers on the latest reported figures

  • AKBA's LTM Mar 2026 research & development of $67.09M is the 5th highest of the 10 companies compared; the peer median is $56.29M.
  • Its year-over-year change of +78.1% is the highest of 9, against a peer median of +35.1%.
  • Research & development amounts to 28.9% of revenue for AKBA, versus a peer median of 104.3%.
AKBA Competitors Peer median
Research & Development for AKBA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
FDMT4D Molecular Therapeutics, Inc.LTM Mar 2026$219.98M +42.7%+34.6%249.3%
GOSSGossamer Bio, Inc.LTM Mar 2026$186.6M +29.5%+0.6%336.0%
OLMAOlema Pharmaceuticals, Inc.LTM Mar 2026$176.31M +40.8%+24.2%—
PRTAProthena Corporation plcLTM Mar 2026$96.67M -53.8%-0.2%166.8%
AKBAAkebia Therapeutics, Inc.LTM Mar 2026$67.09M +78.1%-27.8%28.9%
CMPXCompass Therapeutics, Inc.LTM Mar 2026$56.29M +22.7%+23.1%—
KALVKalVista Pharmaceuticals, Inc.LTM Dec 2025$48.42M ——41.8%
CRVSCorvus Pharmaceuticals, Inc.LTM Mar 2026$37.44M +64.5%+11.3%—
RIGLRigel Pharmaceuticals, Inc.LTM Mar 2026$36.54M +41.7%-17.9%12.2%
ZVRAZevra Therapeutics, Inc.LTM Mar 2026$13.88M -59.9%-13.7%11.3%
Peer median (excluding AKBA) $56.29M+35.1%+5.9%104.3%

Competitors are the stored peer set for AKBA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue211.65M292.48M194.62M160.18M236.2M
Cost of Revenue81.49M22.5M74.15M63.18M39.46M
Gross Profit130.16M269.99M120.47M97M196.73M
Gross Margin61.5%92.3%61.9%60.6%83.3%
Research & Development147.85M165.99M63.08M37.65M62.36M
Selling, General & Admin174.14M138.6M100.23M106.55M107.48M
Operating Expenses394.66M350.77M166.73M147.48M173.24M
Depreciation & Amortization37.97M37.7M37.63M37.5M1.27M
EBITDA(189.91M)3.06M(8.27M)(13.72M)21.73M
EBITDA Margin-89.7%1.0%-4.2%-8.6%9.2%
Operating Income(264.5M)(80.78M)(46.26M)(50.47M)23.5M
Operating Margin-125.0%-27.6%-23.8%-31.5%9.9%
Interest Income00000
Interest Expense19.94M15.69M6.03M18.19M24.18M
Other Income / Expenses(17.52M)(13.45M)(5.67M)(18.94M)(27.22M)
Income Before Tax(282.02M)(94.23M)(51.93M)(69.41M)(3.72M)
Pre-Tax Margin-133.3%-32.2%-26.7%-43.3%-1.6%
Income Tax Expense00001.62M
Net Income(282.02M)(94.23M)(51.93M)(69.41M)(5.35M)
Net Margin-133.3%-32.2%-26.7%-43.3%-2.3%
EPS (Basic)(1.48)(0.58)(0.28)(0.33)(0.02)
EPS (Diluted)(1.48)(0.58)(0.28)(0.33)(0.02)
Weighted Avg Shares165.95M182.78M187.47M210.95M257.16M
Weighted Avg Shares (Diluted)165.95M182.78M187.47M210.95M257.16M

Akebia Therapeutics, Inc.

NASDAQ:AKBA

Intrinsic Alpha fair value

Locked

Current Price

$0.41

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.